Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]

  • Asmaa Gomaa, Naglaa Allam, Aisha Elsharkawy, Mohamed El Kassas, Imam Waked
  • Hepatic Medicine Evidence and Research, July 2017, Dove Medical Press
  • DOI: 10.2147/hmer.s143866


What is it about?

Hepatitis C virus (HCV) infection is a major public health burden in Egypt. In this review, we demonstrate the prevalence results of both surveys and analyze the difference in the results. The overall HCV prevalence is estimated to be declining. A mathematical model shows that by increasing the rate of treatment, the expected number of patients will decline significantly in 2030. The economic burden will continue to grow, but a model shows that the introduction of highly effective therapies will result in a significant reduction in the cumulative total economic burden of HCV by 2030. National Committee for Control of Viral Hepatitis has been established to implement an integrated nationwide strategy to provide patient care and ensure global treatment access.

Why is it important?

The importance of this review that it demonstrate and discuss part of the national program in Egypt that has been developed to eradicate HCV . Explaining management strategies may be of help to other resource limited countries. Egypt is in the way to achieve its goal of HCV eradication soon.


Aisha Elsharkawy

It is an important review, will be suitable for readers to know more about HCV in EGYPT and to compare it with HCV in other countries

open access logoRead Publication


The following have contributed to this page: Aisha Elsharkawy and Mohamed El Kassas